scholarly journals Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2

2021 ◽  
Author(s):  
Sohini Sengupta ◽  
Anil Handoo ◽  
Rajesh Pande ◽  
R. K. Kapoor
Keyword(s):  
Retrospective Analysis ◽  
Clinical Laboratory ◽  
Laboratory Parameters

Propofol-based sedation does not negatively influence oxygenator running time compared to midazolam in patients with extracorporeal membrane oxygenation

2019 ◽  
Vol 42 (5) ◽  
pp. 233-240 ◽  
Author(s):  
Wolfgang Lamm ◽  
Bernhard Nagler ◽  
Alexander Hermann ◽  
Oliver Robak ◽  
Peter Schellongowski ◽  
...  
Keyword(s):  
Parenteral Nutrition ◽  
Extracorporeal Membrane Oxygenation ◽  
Retrospective Analysis ◽  
Partial Thromboplastin Time ◽  
Activated Partial Thromboplastin Time ◽  
Free Hemoglobin ◽  
Running Time ◽  
Laboratory Parameters ◽  
Membrane Oxygenation ◽  
Midazolam Group

Objective: Patients on extracorporeal membrane oxygenation are frequently in need for sedation. Use of propofol has been associated with impaired oxygenator function due to adsorption to the membrane as well as lipid load. The aim of our retrospective analysis was to compare two different sedation regimens containing either propofol or midazolam with respect to oxygenator running time. Methods: Midazolam was used in 73 patients whereas propofol was used in 49 patients, respectively. In the propofol group, veno-arterial–extracorporeal membrane oxygenation was used predominantly (84%), while veno-venous–extracorporeal membrane oxygenation was used more often in the midazolam group (64%). Results: Oxygenator running time until first exchange was 7 days in both groups ( p = 0.759). No statistically significant differences could be observed between the subgroup of patients receiving lipid-free (n = 24) and lipid-containing (n = 31) parenteral nutrition, respectively. Laboratory parameters like triglycerides, free hemoglobin, fibrinogen, platelets, and activated partial thromboplastin time were not significantly different between both sedation regimens ( p = 0.462, p = 0.489, p = 0.960, p = 0.134, and p = 0.843) and were not associated with oxygenator running time. Conclusion: The use of propofol as sedative seems suitable in patients undergoing extracorporeal membrane oxygenation therapy.

scholarly journals Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (10) ◽  
pp. e0239802 ◽  
Author(s):  
Jude Moutchia ◽  
Pratik Pokharel ◽  
Aldiona Kerri ◽  
Kaodi McGaw ◽  
Shreeshti Uchai ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Laboratory ◽  
Meta Analysis ◽  
Laboratory Parameters ◽  
Novel Coronavirus

scholarly journals Effect of Seasonal Variation on Adult Clinical Laboratory Parameters in Rwanda, Zambia, and Uganda: Implications for HIV Biomedical Prevention Trials

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e105089 ◽  
Author(s):  
Eugene Ruzagira ◽  
Andrew Abaasa ◽  
Etienne Karita ◽  
Joseph Mulenga ◽  
William Kilembe ◽  
...  
Keyword(s):  
Seasonal Variation ◽  
Clinical Laboratory ◽  
Laboratory Parameters ◽  
Biomedical Prevention ◽  
Prevention Trials

Mo1208 Effect of Adalimumab on Clinical Laboratory Parameters in Pediatric Crohn's Disease Patients From IMAgINE 1

2015 ◽  
Vol 148 (4) ◽  
pp. S-638-S-639 ◽  
Author(s):  
Jeffrey S. Hyams ◽  
Joel R. Rosh ◽  
James Markowitz ◽  
Jaroslaw Kierkus ◽  
Marla Dubinsky ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Laboratory ◽  
Laboratory Parameters

scholarly journals Diagnostic Value of Clinical and Laboratory Parameters in the Diagnosis of Non-Specific Ulcer Colitis

2020 ◽  
Vol 5 (6) ◽  
pp. 136-140
Author(s):  
A. P. Lutsyk ◽  
◽  
E. I. Shorikov ◽  
Keyword(s):  
Computed Tomography ◽  
Ulcerative Colitis ◽  
Abdominal Pain ◽  
Clinical Laboratory ◽  
False Negative ◽  
Diagnostic Value ◽  
Fecal Calprotectin ◽  
Clinical Indicators ◽  
Laboratory Parameters ◽  
Highly Sensitive

The etiology of ulcerative colitis is still unknown. The number of works dealing with a comprehensive assessment of the role of clinical, laboratory, endoscopic, as well as immunological and genetic factors in the formation of unfavorable forms of ulcerative colitis is extremely small, and their results seem ambiguous. The purpose of the study was to determine the diagnostic value of clinical and laboratory signs in relation to verification of the depth of endoscopic lesion in patients with ulcerative colitis. Material and methods. 68 patients with ulcerative colitis (36 men and 32 women) were examined. The average age was 38.0±4.5 years. All patients were inspected with colonoscopy. Clinical, laboratory, immunological research, as well as computed tomography were carried out. Disease activity was determined according to the Truelove-Witts classification. Results and discussion. The obtained results showed that all intestinal symptoms (stool frequency more than 4 times a day, abdominal pain, tenesmus, hematochezia) had a reliable diagnostic value (р<0.05) in the presence of contact vulnerability and ulceration of the intestinal mucosa. The greatest sensitivity was characteristic of abdominal pain (94.1 [84.1-96.3]). It was found that the diagnostic sensitivity of tachycardia and uveitis is unreliable. Among the clinical indicators, the greatest diagnostic value was established for anemic syndrome (p<0.05), among additional signs was for sclerosing cholangitis (p<0.05). With regard to laboratory parameters, the diagnostic value was proven for hemoglobin levels <90 g/l (p<0.05) and hypoproteinemia (p<0.05). The diagnostic concentration of C-reactive protein for predicting a mucosal defect was determined at a level of more than 10 mg/L in terms of sensitivity and specificity (p<0.05). The level of fecal calprotectin more than 200 μg/g (p<0.05) was highly sensitive and highly specific. Conclusion. The study showed the possibilities of computed tomography for verifying of ulcerative defects. The method is highly sensitive in ulcerative colitis (sensitivity is 95.6 [85.9-97.1], specificity is (96.7 [83.3-99.4]), with a low probability of false-negative and false-positive results (p<0.05)

scholarly journals Hemophagocytic Lymphohistiocytosis: Retrospective Analysis for Prognostic Factors

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4615-4615 ◽  
Author(s):  
Bhagirathbhai Dholaria ◽  
William A Hammond ◽  
Amanda Shreders ◽  
Sarah Robinson ◽  
Taimur Sher
Keyword(s):  
Retrospective Analysis ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Nk Cell ◽  
Clinical Laboratory ◽  
Conflicts Of Interest ◽  
Cell Activity ◽  
Significant Risk ◽  
P Value ◽  
Significant Heterogeneity ◽  
Treatment Pathways

Abstract Background Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic inflammatory condition. Due to rarity of the cases, it presents difficulties in diagnosis and management. Survival remains poor despite aggressive chemotherapy. Objective Patient outcomes varied markedly despite standardize therapy. Reliable prognostic disease markers may help to tailor intensity of therapy and predict long term outcomes. We attempt to look for variables associated with difference in mortality within 30 days of diagnosis. Methods We performed a retrospective search on mayo clinic patient database for the patients with the diagnosis of HLH from 2005 to 2015. HLH-04 criteria were used to select the study population. Patients were divided in two groups based on survival after the diagnosis. We analyzed different clinical and laboratory parameters to detect difference between the patients expired within 30 days of diagnosis and who survived longer than 30 days. Baseline Characteristics: Demographics: 40 patients were included in the analysis who met HLH- 04 criteria. Mean age was 49 years, 40% (16/40) were female and 60% (24/40) were male. Underlying HLH etiology was malignancy 37% (15/40), infection 20% (8/40), rheumatological 17% (7/40), idiopathic 20% (8/40). Two patients were peripartum and one with Kikuchi syndrome. EBV DNA PCR were positive in 32% (13/40) of patients. Table 1 show clinical and laboratory characteristics according to HLH-04 criteria. Treatment: Steroids were used in 92% (37/40), etoposide was used in 55% (22/40), and HLH 04 protocol (Etoposide/dexamethasone/cyclosporine) was used in 40% (16/40) of the patients. IVIG was used in 13% with underlying rheumatological process. Mean follow up was 57 weeks (0.1 to 336 weeks) for the whole group. Total 40% (16/40) died within 30 days of diagnosis. Results Risk of 30-days mortality was significantly higher in the patients with ferritin >5000 mcg/L at the time of diagnosis and age > 55 years. Out of total 40 patients, 54% (12/22) died in ferritin >5000mcg/L group and 22% (4/18) died in ferritin < 5000 mcg/L group within 30 days. (p-0.03) Death rate within 30 days was 65% (11/17) with age > 55 years and 22% (5/23) with age < 55 years at the time of diagnosis of HLH. (p-0.05) No difference between the groups in terms of gender, EBV positivity, underlying etiology and etoposide use was found in 30 days mortality. Table 2 summarizes the findings. Discussion HLH is a complex disorder with significant heterogeneity in terms of underlying etiology and response to treatments. Diagnosis is based on a set of clinical and investigational parameters. Most commonly used criteria are HLH-04. Treatment involves rapid immunosuppression with steroids, chemotherapy and calcineurin inhibitors. Previous retrospective studies have pointed out different risk factors associated with poor survival, which are malignancy, hypoalbuminemia, elevated creatinine and bilirubin. Ours is a relatively small retrospective analysis, but it shows significant prognostic value to elevated ferritin (>5000 mcg/L) at the time of diagnosis and age > 55 years. Survival remains poor in high risk patients despite aggressive therapy. Biological agents (IL1 and IL6 blockage) may provide new realm of therapy with tolerable toxicity profile. Conclusion Elevated ferritin at the time of diagnosis and older age are associated with significant risk of 30 day mortality in HLH. These factors can be incorporated in future clinical trials to choose different treatment pathways. Table. Clinical and laboratory characteristics according to HLH- 04 criteria Clinical/laboratory manifestation Presence of HLH 04 criteria (%) Fever > 38.5C 36/40 90 Splenomegaly 30/40 75 Hemoglobin < 9g/dl 22/40 55 ANC < 1000/microL 14/40 35 Platelets < 100, 000/microL 31/40 77 Triglyceride > 265 mg/dl 22/40 55 Ferritin > 500 mcg/L 36/40 90 Fibrinogen <150 mg/dl 12/38 31 sIL2- R > 1000u/ml 13/14 92 Low NK - cell activity 13/15 86 Presence of hemophagocytosis 33/39 84 Table 2. Difference in clinical variables based on survival after the diagnosis of HLH Survival < 30 days Survival > 30 days P value Age (years) 62 40 0.0004 Median time to start treatment (weeks) 40.7 8.6 0.23 Baseline ferritin (mcg/L) 32866 10667 0.01 Peak ferritin (mcg/L) 45870 29894 0.26 Albumin (g/dL) 2.3 2.6 0.41 LDH (U/L) 1271 720 0.51 Bilirubin (mg/dL) 8.9 4.5 0.14 Triglyceride (mg/dl) 260 276 0.70 Disclosures No relevant conflicts of interest to declare.

scholarly journals Clinical retrospective analysis of 70 discharged patients with the Coronavirus disease 2019 (COVID-19) in Hangzhou, Zhejiang Province

2020 ◽  
Author(s):  
Zhongbao Zuo ◽  
Jing Wu ◽  
Miaochan Wang ◽  
Yujiao Jin ◽  
Wenyan Yu ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Laboratory ◽  
Close Contact ◽  
Ground Glass Opacity ◽  
Median Number ◽  
Tomographic Images ◽  
Illness Onset ◽  
Computed Tomographic ◽  
Discharged Patients ◽  
Ct Data

Abstract Background Since the Coronavirus Disease 2019 (COVID-19) was first identified in Wuhan, China, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pathogen, the disease has been found in many countries. Considering the lack of effective drugs and rapid spread of COVID-19, we did a clinical detailed retrospective analysis of 70 discharged patients which can help us to better determine the clinical features of the disease.Method We collected demographic, epidemiological, clinical, laboratory, and chest computed tomographic (CT) data from patients’ hospital records, the time period were from hospitalization day1 to day7 and hospitalization last day. The retrospective study totally included 70 COVID-19 patients.Results The median age was 43 (IQR: 34-56) years. 41 (58.6%) patients were female, and there were 33 (47.1%) patients who were hospitalized more than 14 days. 18 (25.7%) patients were residents of Wuhan or recently travelled to Wuhan, 38 (54.3%) patients were having a close contact with the COVID-19 patients. The most common pre-existing diseases were liver disease (15.7%), hypertension (12.9%), renal disease (8.6), lung disease (5.7%). The time from illness onset to hospitalization was 4 (IQR: 2-7) days. The most common treatment regimen was Lopinavir/ritonavir (LPV) + Interferon alpha inhalation (IAI) + Arbidol. Compared with hospitalization day1, White blood cell count, C-reacting protein, Potassium, Aspartate aminotransferase, Lactate dehydrogenase, and Lactic acid were significantly different than hospitalization day-last. The median number of times a patients receiving chest computed tomography (CT) from day1 to day7 was 3 (IQR: 3-4). The typical chest computed tomographic images were patchy shadows and ground glass opacity.Conclusion Currently, there are no specific antiviral therapies for COVID-19. 70 COVID-19 patients in our study responded positively to treatment during the two-week period. For those discharged patients with abnormal results, more attention is needed in the future studies to control the transmission.

Sign in / Sign up

Export Citation Format

Share Document